Andrew A. F. Hack, M.D., Ph.D., has served as a member of our Board of Directors since January 2017. Dr. Hack has served as a Partner of Bain Capital since March 2019. Before joining Bain Capital, Dr. Hack was the Chief Financial Officer of Editas Medicine, Inc., a biotechnology company, from July 2015 through March 2019. Dr. Hack has served on the board of directors of Nuvalent, Inc., a biotechnology company, or Nuvalent, since April 2021. He previously served as a director of Dynavax Technologies Corp., a biopharmaceutical company, from August 2019 to August 2023; of BCLS Acquisition Corp. from October 2020 until November 2022; of Allena Pharmaceuticals, Inc., from June 2018 to June 2021; and of Atea Pharmaceuticals, Inc., a biopharmaceutical company, from May 2020 to June 2021. Dr. Hack received an A.B. in biology with special honors, an M.D. and a Ph.D. in molecular genetics and cell biology from the University of Chicago.